Business Context and Reporting Period
This Form 8-K was filed by Lion Biotechnologies, Inc. on November 5, 2015. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2015. The registrant is incorporated in Nevada and maintains its principal executive offices in New York, New York.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It directs readers to the referenced press release for the specific results of operations and financial condition for the periods ended September 30, 2015.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The document functions solely as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 5, 2015) for actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones or clinical trial updates mentioned in the referenced press release.
- Confirm the company's current cash runway and burn rate as disclosed in the full press release.
- Note that the registrant name in the filing is Lion Biotechnologies, Inc., distinct from the metadata field "IOVANCE BIOTHERAPEUTICS, INC."